Article: Study results from A. Ahmed and colleagues update understanding of vascular endothelial growth factor.

In this recent report published in the journal Clinical and Experimental Ophthalmology, researchers in Balgat, Turkey conducted a study "To investigate the effect of bevacizumab in an experimental rabbit model of corneal neovascularization. The right eyes of 24 white New Zealand rabbits were included in a corneal neovascularization model using alkaline burn."

"They were divided into four groups. Topical bevacizumab was installed three times daily in group 1, 5 mg bevacizumab subconjunctivally every 2 days in group 2, 10 mg bevacizumab subconjunctivally every 2 days in group 3 and 0.2 cc of normal saline in the same way in group 4 (control group). All eyes were ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!